MOLECULAR PARTNERS AG (MOLN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in CHF.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Quarterly

0 4M 8M 12M Q2 '22: 11.7M Q2 '23: 415K Q2 '24: 1.6M Q2 '25: 0 Q2 '22 Q2 '23 Q2 '24 Q2 '25

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q2 '22: -6.3M Q2 '23: -15.9M Q2 '24: -16M Q2 '25: -17.3M Q2 '22 Q2 '23 Q2 '24 Q2 '25

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q2 '22: -4.5M Q2 '23: -16M Q2 '24: -15.1M Q2 '25: -20.4M Q2 '22 Q2 '23 Q2 '24 Q2 '25

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '22: 32.5M Q2 '23: 32.8M Q2 '24: 33.2M Q2 '25: 37.4M Q2 '22 Q2 '23 Q2 '24 Q2 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.